Equillium reports third quarter 2024 financial results and provides corporate and clinical updates

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2024 and provided corporate and clinical updates. “at the end of october we announced that our partnership with ono pharmaceutical had ended following substantial non-dilutive financing that has fully fund.
EQ Ratings Summary
EQ Quant Ranking